Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,462.60 | 40.90 | 0.49% |
| CAC 40 | 7,743.75 | 49.31 | 0.64% |
| DAX 40 | 23,499.32 | 146.63 | 0.63% |
| Dow JONES (US) | 41,269.78 | 98.67 | -0.24% |
| FTSE 100 | 8,554.80 | 23.19 | 0.27% |
| HKSE | 22,867.74 | 91.82 | 0.40% |
| NASDAQ | 17,929.22 | 1.08 | 0.01% |
| Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,662.72 | 1.22 | -0.02% |
| S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
| SSE Composite Index | 3,342.00 | 10.00 | -0.30% |